OOIR: Observatory of International Research

Papers

(The TQCC of Expert Opinion on Drug Discovery is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
What is the plausibility that all drugs will be designed by computers by the end of the decade?	159
Advances in ion channel high throughput screening: where are we in 2023?	124
Scaffold hopping approaches for dual-target antitumor drug discovery: opportunities and challenges	78
Lessons learned from phenotypic drug discovery efforts	76
Reality check: lipid-oligonucleotide conjugates for therapeutic applications	73
An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19)	69
The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer	68
γ-Secretase: once and future drug target for Alzheimer’s disease	66
Advances in the discovery of drugs that treat pulmonary arterial hypertension	57
Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery	54
Strategies for targeting RNA with small molecule drugs	51
Understanding the impact of binding free energy and kinetics calculations in modern drug discovery	49
Methods in marine natural product drug discovery: what’s new?	46
Tools and techniques for the discovery of therapeutic aptamers: recent advances	45
A comprehensive update on the use of molecular topology applications for anti-infective drug discovery	43
An update on knowledge graphs and their current and potential applications in drug discovery	42
Guided structure-based ligand identification and design via artificial intelligence modeling	37
The machine learning life cycle and the cloud: implications for drug discovery	37
Calcium channel blockers’ contribution to overcoming Current drug discovery challenges in Alzheimer’s disease	36
C. elegans : a prominent platform for modeling and drug screening in neurological disorders	36
The rules often neglected in current medicinal chemistry	34
A cautionary tale of paradox and false positives in cannabidiol research	34
Molecular hybridization: a powerful tool for multitarget drug discovery	32
Virtual screening: hope, hype, and the fine line in between	32
Water in drug design: pitfalls and good practices	31

Acoustic ejection mass spectrometry: fundamentals and applications in high-throughput drug discovery	29
The discovery and development of RNA-based therapies for treatment of HIV-1 infection	28
An overview of the preclinical discovery and development of tezepelumab for the treatment of asthma	27
Recent applications of positron emission tomographic (PET) imaging in psychiatric drug discovery	27
Drug design strategies for the treatment azole-resistant candidiasis	27
Novel hydrogels: are they poised to transform 3D cell-based assay systems in early drug discovery?	27
Murine models of dengue virus infection for novel drug discovery	26
Correction	25
Animal models of chronic obstructive pulmonary disease and their role in drug discovery and development: a critical review	25
Revisiting experimental models of erectile dysfunction and their value in drug discovery and development	24
Current challenges and future perspectives of drug discovery in China	24
Innovative strategies for the discovery of new drugs against alopecia areata: taking aim at the immune system	24
Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancer	23
Lessons learned from the discovery and development of the sesquiterpene lactones in cancer therapy and prevention	23
Success stories of AI in drug discovery - where do things stand?	23
Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach	23
What are the challenges with multi-targeted drug design for complex diseases?	23
Metabolomics in antimicrobial drug discovery	22
The human NTG model of migraine in drug discovery and development	22
The application of pancreatic cancer organoids for novel drug discovery	22
Advances in the design, discovery, and optimization of aurora kinase inhibitors as anticancer agents	21
High performance-oriented computer aided drug design approaches in the exascale era	21
Designing multi-target drugs for the treatment of major depressive disorder	21
Novel strategies for the development of hand, foot, and mouth disease vaccines and antiviral therapies	20
Advances in the discovery of new chemotypes through ultra-large library docking	20
PTPN22: structure, function, and developments in inhibitor discovery with applications for immunotherapy	20
Unmasking allosteric-binding sites: novel targets for GPCR drug discovery	20
What have we learnt from past failures in Alzheimer’s disease drug discovery?	20
Targeted Degradation of Structured RNAs via Ribonuclease-Targeting Chimeras (RiboTacs)	20
The design and discovery of phospholipase A₂ inhibitors for the treatment of inflammatory diseases	20
Mapping strategies towards improved external validity in preclinical translational research	19
A comprehensive update on the application of high-throughput fluorescence imaging for novel drug discovery	19
Avenues for antifungal drug discovery and development: where to now?	18
An overview on small molecules acting as broad-spectrum agents for yellow fever infection	17
Latest developments in engineered skeletal muscle tissues for drug discovery and development	17
Advances in structure-activity relationships of HDAC inhibitors as HIV latency-reversing agents	16
In silico drug design strategies for discovering novel tuberculosis therapeutics	16
How do we address neglected sulfur pharmacophores in drug discovery?	16
Novel avenues for identification of new antifungal drugs and current challenges	16
The discovery and development of novel treatment strategies for filoviruses	16
Data processing for high-throughput mass spectrometry in drug discovery	16
Artificial intelligence for small molecule anticancer drug discovery	15
The role of rodent behavioral models of schizophrenia in the ongoing search for novel antipsychotics	15
Efflux in Gram-negative bacteria: what are the latest opportunities for drug discovery?	15
The latest advances in high content screening in microfluidic devices	15
What is the future of click chemistry in drug discovery and development?	15
Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer’s disease	14
The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma	14
Artificial intelligence in early drug discovery enabling precision medicine	14
Targeting protein-protein interactions with low molecular weight and short peptide modulators: insights on disease pathways and starting points for drug discovery	14

The preclinical discovery and development of zanubrutinib for the treatment of chronic lymphocytic leukemia	14
An overview of rational design of mRNA-based therapeutics and vaccines	14
Innovative drug discovery strategies in epilepsy: integrating next-generation syndrome-specific mouse models to address pharmacoresistance and epileptogenesis	14
Future prospects of accelerating neuroactive drug discovery with high-throughput behavioral phenotyping	14
Validation guidelines for drug-target prediction methods	13
Library size in virtual screening: is it truly a number’s game?	13
Recent animal models of bladder cancer and their application in drug discovery: an update of the literature	13
The problem of antimalarial resistance and its implications for drug discovery	13
Investigating novel pharmacological strategies for treatment-resistant depression: focus on new mechanisms and approaches	13
Current views on in vivo models for breast cancer research and related drug development	13
Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism	12
Strategies for the drug discovery and development of taxane anticancer therapeutics	12
Long non-coding RNA-targeting therapeutics: discovery and development update	12
3D bioprinting for organ and organoid models and disease modeling	12
Using automated patch clamp electrophysiology platforms in ion channel drug discovery: an industry perspective	12
Molecular glue degraders: exciting opportunities for novel drug discovery	12
The design and discovery of topoisomerase I inhibitors as anticancer therapies	12
An update on preclinical pregnancy models of Zika virus infection for drug and vaccine discovery	12
Understanding the role of cGAS-STING signaling in ischemic stroke: a new avenue for drug discovery	12
Have spirocyclic scaffolds been properly utilized in recent drug discovery efforts?	12
Open resources for chemical probes and their implications for future drug discovery	11
Lessons learnt from machine learning in early stages of drug discovery	11
Fragment-based approaches to discover ligands for tumor-specific E3 ligases	11
Challenges with the discovery of RNA-based therapeutics for flaviviruses	11
Perspectives on the success of plasma lipidomics in cardiovascular drug discovery and future challenges	11
Animal models of Kabuki syndrome and their applicability to novel drug discovery	11
Linkers in fragment-based drug design: an overview of the literature	11
Designing drugs when there is low data availability: one-shot learning and other approaches to face the issues of a long-term concern	11
Targeting guanine nucleotide exchange factors for novel cancer drug discovery	11
Role of computational and structural biology in the development of small-molecule modulators of the spliceosome	10
An overview of the latest in state-of-the-art murine models for prostate cancer	10
An overview of ProTide technology and its implications to drug discovery	10
Notice of duplicate publication: What are the practical, ethical and pathobiological considerations in the use of minipigs as an animal model in drug discovery for acute radiation syndrome and delayed	10
Is it possible to design a clinically viable heroin vaccine? The progress and pitfalls	10
Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers	10
Perspectives on the design and discovery of α-ketoamide inhibitors for the treatment of novel coronavirus: where do we stand and where do we go?	10
Recent advances in cellular models for discovering prion disease therapeutics	10
Approaches for development of LAG-3 inhibitors and the promise they hold as anticancer agents	10